Skip to main content
Medartis Holding AG logo

Medartis Holding AG — Investor Relations & Filings

Ticker · MED ISIN · CH0386200239 LEI · 506700VUSP6HG3F28846 SW Manufacturing
Open in API
Filings indexed 101 across all filing types
Latest filing 2024-07-09 Board/Management Inform…
Country CH Switzerland
Listing SW MED

About Medartis Holding AG

https://www.medartis.com/

Medartis Holding AG is a medical device company that develops, manufactures, and distributes implant solutions for the surgical fixation of bone fractures. The company provides precision-engineered system solutions, including titanium screws, plates, and surgical instruments. Its primary focus is on osteosynthesis for the upper and lower extremities, as well as for cranio-maxillofacial surgery. Medartis offers comprehensive solutions designed to support surgeons and facilitate optimal patient care in fracture fixation procedures.

Recent filings

Filing Released Lang Actions
Basel, 9. Juli 2024   Matthias Schupp zum CEO von Medartis ernannt
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and its primary content is the announcement that Matthias Schupp has been appointed as the new CEO, succeeding Christoph Brönnimann. This constitutes an announcement of a change in senior management. This directly matches the definition for Board/Management Information (MANG). Although it is an 'Ad hoc-Mitteilung' (which could sometimes fall under RNS), the specific subject matter (CEO appointment) makes MANG the most precise classification.
2024-07-09 German
Basel, 11th June 2024 Medartis announces resignation of CEO Christoph Bronnimann
Board/Management Information Classification · 100% confidence The document is a short press release dated June 11, 2024, announcing the resignation of the CEO, Christoph Brönnimann. This type of announcement, detailing changes in senior management, directly corresponds to the definition of 'Board/Management Information'. The filing explicitly mentions 'Ad-hoc' release pursuant to Art. 53 LR, which is typical for material, non-public information like executive changes. It is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A). Therefore, the classification is MANG.
2024-06-11 English
Basel, 11th June 2024   Medartis announces resignation of CEO Christoph Brönnimann
Board/Management Information Classification · 100% confidence The document is an 'Ad hoc announcement' explicitly stating the resignation of the CEO, Christoph Brönnimann. This type of announcement concerns a change in senior management personnel. Based on the provided definitions, the most appropriate classification is 'Board/Management Information' (MANG). The document is short and focuses entirely on this personnel change, not on financial results (ER/IR) or a general regulatory filing (RNS).
2024-06-11 English
Basel, 11. Juni 2024   Medartis gibt den Rücktritt von CEO Christoph Brönnimann bekannt
Board/Management Information Classification · 100% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and its primary content announces the resignation of the CEO, Christoph Brönnimann. This directly relates to a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is a formal announcement, not a full report or a general regulatory filing fallback.
2024-06-11 German
Medartis successfully places CHF 115.8 million convertible bonds due 2031
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated April 4, 2024, explicitly stating it is a 'Release of an ad hoc announcement pursuant to Art. 53 LR'. The content details the 'successful placement of CHF 115.8 million convertible bonds due 2031'. This action—issuing new debt/securities to raise capital—falls directly under the definition of a Capital/Financing Update. It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2024-04-04 English
Medartis successfully places CHF 115.8 million convertible bonds due 2031
Capital/Financing Update Classification · 99% confidence The document is titled 'Ad hoc announcement pursuant to Art. 53 LR' and explicitly states 'Medartis successfully places CHF 115.8 million convertible bonds due 2031'. This content details a specific financing activity—the placement of convertible bonds—which involves raising capital. This aligns directly with the definition of 'Capital/Financing Update' (CAP). Although it is an announcement, the core subject matter is the financing event itself, not just the announcement of a report, making CAP a more specific fit than RPA or RNS. The document is substantial enough (12,742 chars) to contain the details of the placement rather than just being a brief notice pointing to an attached document.
2024-04-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.